



Clinical trial results:

A phase III, randomized, double-blind, placebo-controlled multi-center study of subcutaneous secukinumab (150 mg and 300 mg) in prefilled syringe to demonstrate efficacy (including inhibition of structural damage), safety, and tolerability up to 2 years in subjects with active psoriatic arthritis (FUTURE 5)

Summary

EudraCT number	2015-000050-38
Trial protocol	LT IE HU NL ES DE IT AT LV DK CZ FI EE GR
Global end of trial date	24 January 2019

Results information

Result version number	v1 (current)
This version publication date	09 February 2020
First version publication date	09 February 2020

Trial information

Trial identification

Sponsor protocol code	CAIN457F2342
-----------------------	--------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02404350
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Novartis PharmaAG
Sponsor organisation address	CH-4002, Basel, Switzerland,
Public contact	Clinical Disclosure Office, Novartis PharmaAG, 41 613241111, novartis.email@novartis.com
Scientific contact	Clinical Disclosure Office, Novartis PharmaAG, 41 613241111, Novartis.email@novartis.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	07 August 2019
Is this the analysis of the primary completion data?	Yes
Primary completion date	31 August 2017
Global end of trial reached?	Yes
Global end of trial date	24 January 2019
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The primary objective was to demonstrate that the efficacy of secukinumab 150 mg sc (with or without loading regimen), or 300 mg sc with loading regimen, at Week 16 is superior to placebo based on proportion of patients with active psoriatic arthritis (PsA) achieving American College of Rheumatology 20 (ACR20) response.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines. All the local regulatory requirements pertinent to safety of trial subjects were also followed during the conduct of the trial.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	31 August 2015
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Austria: 30
Country: Number of subjects enrolled	Latvia: 8
Country: Number of subjects enrolled	Lithuania: 52
Country: Number of subjects enrolled	Hungary: 36
Country: Number of subjects enrolled	Spain: 65
Country: Number of subjects enrolled	United States: 103
Country: Number of subjects enrolled	Russian Federation: 123
Country: Number of subjects enrolled	Estonia: 15
Country: Number of subjects enrolled	Italy: 10
Country: Number of subjects enrolled	Netherlands: 13
Country: Number of subjects enrolled	Czech Republic: 80
Country: Number of subjects enrolled	United Kingdom: 98
Country: Number of subjects enrolled	Germany: 59
Country: Number of subjects enrolled	Canada: 35
Country: Number of subjects enrolled	Denmark: 2
Country: Number of subjects enrolled	Finland: 15
Country: Number of subjects enrolled	Greece: 22
Country: Number of subjects enrolled	Israel: 41

Country: Number of subjects enrolled	Thailand: 13
Country: Number of subjects enrolled	Vietnam: 27
Country: Number of subjects enrolled	Philippines: 23
Country: Number of subjects enrolled	Sweden: 4
Country: Number of subjects enrolled	Mexico: 34
Country: Number of subjects enrolled	Ireland: 4
Country: Number of subjects enrolled	India: 38
Country: Number of subjects enrolled	Chile: 23
Country: Number of subjects enrolled	Guatemala: 12
Country: Number of subjects enrolled	Argentina: 11
Worldwide total number of subjects	996
EEA total number of subjects	513

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	900
From 65 to 84 years	96
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Study was conducted at 173 centers in 28 countries.

Pre-assignment

Screening details:

999 were randomized and 996 were randomized and dosed, of which 932 participants completed 24 weeks of treatment. Out of the 64 participants who discontinued the most common reasons were participant/guardian decision (32) and adverse events (16).

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Investigator, Monitor, Carer, Subject

Blinding implementation details:

double-blind

Arms

Are arms mutually exclusive?	Yes
Arm title	Secukinumab 150 mg Without Load

Arm description:

Participants were subcutaneously (s.c.) administered with 150 milligrams (mg) of secukinumab as 1 milliliter (mL) Pre-Filled Syringe (PFS) and secukinumab matching placebo (1 mL PFS) at baseline. Participants received secukinumab matching placebo (2*1 mL PFS) at Weeks 1, 2 and 3. From week 4 participants received secukinumab 150 mg (1 mL PFS) and secukinumab matching placebo (1 mL PFS) every four weeks up to 100 weeks.

Arm type	Experimental
Investigational medicinal product name	Secukinumab
Investigational medicinal product code	
Other name	AIN457F
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Secukinumab 150 mg Without Load sc

Arm title	Secukinumab 150 mg With Load
------------------	------------------------------

Arm description:

Participants were s.c. administered with 150 mg of secukinumab as 1 mL PFS and secukinumab matching placebo (1 mL PFS) at baseline, weeks 1, 2 and 3, followed by dosing every four weeks starting at Week 4 up to 100.

Arm type	Experimental
Investigational medicinal product name	secukinumab
Investigational medicinal product code	
Other name	AIN457F
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Secukinumab 150 mg With Load

Arm title	Secukinumab 300 mg With Load
------------------	------------------------------

Arm description:

Participants were s.c. administered with 300 mg of secukinumab as 2*1 mL PFS (150 mg dose) at baseline, weeks 1, 2 and 3, followed by dosing every four weeks starting at Week 4 up to 100 weeks.

Arm type	Experimental
Investigational medicinal product name	secukinumab
Investigational medicinal product code	
Other name	AIN457F
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Secukinumab 300 mg With Load sc

Arm title	Placebo
------------------	---------

Arm description:

Participants were s.c. administered with secukinumab matching placebo (2*1 mL PFS) at baseline, weeks 1, 2 and 3, followed by dosing every four weeks starting at Week 4. Participants were further randomized to two different treatment sequences in 1:1 ratio at baseline as secukinumab matching placebo till Week 16/24 followed by secukinumab 150 mg every 4 weeks starting at Week 16/24 up to 100 weeks and secukinumab matching placebo till Week 16/24 followed by secukinumab 300 mg every 4 weeks starting at Week 16/24 up to 100 weeks.

Arm type	Experimental
Investigational medicinal product name	placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

sc

Number of subjects in period 1	Secukinumab 150 mg Without Load	Secukinumab 150 mg With Load	Secukinumab 300 mg With Load
Started	222	220	222
Completed	207	214	216
Not completed	15	6	6
Due to Technical problems	-	-	-
Consent withdrawn by subject	7	3	3
Physician decision	1	-	-
Due to Non-compliance with treatment	-	-	-
Adverse event, non-fatal	2	2	3
Pregnancy	-	-	-
Lost to follow-up	2	-	-
Lack of efficacy	3	1	-

Number of subjects in period 1	Placebo
Started	332
Completed	295
Not completed	37

Due to Technical problems	1
Consent withdrawn by subject	19
Physician decision	2
Due to Non-compliance with treatment	1
Adverse event, non-fatal	9
Pregnancy	1
Lost to follow-up	1
Lack of efficacy	3

Baseline characteristics

Reporting groups

Reporting group title	Secukinumab 150 mg Without Load
Reporting group description: Participants were subcutaneously (s.c.) administered with 150 milligrams (mg) of secukinumab as 1 milliliter (mL) Pre-Filled Syringe (PFS) and secukinumab matching placebo (1 mL PFS) at baseline. Participants received secukinumab matching placebo (2*1 mL PFS) at Weeks 1, 2 and 3. From week 4 participants received secukinumab 150 mg (1 mL PFS) and secukinumab matching placebo (1 mL PFS) every four weeks up to 100 weeks.	
Reporting group title	Secukinumab 150 mg With Load
Reporting group description: Participants were s.c. administered with 150 mg of secukinumab as 1 mL PFS and secukinumab matching placebo (1 mL PFS) at baseline, weeks 1, 2 and 3, followed by dosing every four weeks starting at Week 4 up to 100.	
Reporting group title	Secukinumab 300 mg With Load
Reporting group description: Participants were s.c. administered with 300 mg of secukinumab as 2*1 mL PFS (150 mg dose) at baseline, weeks 1, 2 and 3, followed by dosing every four weeks starting at Week 4 up to 100 weeks.	
Reporting group title	Placebo
Reporting group description: Participants were s.c. administered with secukinumab matching placebo (2*1 mL PFS) at baseline, weeks 1, 2 and 3, followed by dosing every four weeks starting at Week 4. Participants were further randomized to two different treatment sequences in 1:1 ratio at baseline as secukinumab matching placebo till Week 16/24 followed by secukinumab 150 mg every 4 weeks starting at Week 16/24 up to 100 weeks and secukinumab matching placebo till Week 16/24 followed by secukinumab 300 mg every 4 weeks starting at Week 16/24 up to 100 weeks.	

Reporting group values	Secukinumab 150 mg Without Load	Secukinumab 150 mg With Load	Secukinumab 300 mg With Load
Number of subjects	222	220	222
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	204	193	202
From 65-84 years	18	27	20
85 years and over	0	0	0
Age Continuous Units: years			
arithmetic mean	48.8	48.4	48.9
standard deviation	± 11.82	± 12.87	± 12.80
Sex: Female, Male Units:			
Female	102	109	114
Male	120	111	108

Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	25	30	31
Not Hispanic or Latino	180	160	174
Unknown or Not Reported	17	30	17
Participants with psoriasis of hands and feet			
Units: Subjects			
Yes	133	135	127
No	89	85	95
Subjects with psoriasis of nail			
Units: Subjects			
Yes	153	135	144
No	69	85	78
Subjects with psoriasis $\geq$ 3% of BSA			
Units: Subjects			
Yes	117	125	110
No	105	95	112

Reporting group values	Placebo	Total	
Number of subjects	332	996	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	301	900	
From 65-84 years	31	96	
85 years and over	0	0	
Age Continuous			
Units: years			
arithmetic mean	49.0		
standard deviation	$\pm$ 12.12	-	
Sex: Female, Male			
Units:			
Female	171	496	
Male	161	500	
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	51	137	
Not Hispanic or Latino	251	765	
Unknown or Not Reported	30	94	
Participants with psoriasis of hands and feet			
Units: Subjects			
Yes	174	569	
No	158	427	

Subjects with psoriasis of nail Units: Subjects			
Yes	231	663	
No	101	333	
Subjects with psoriasis $\geq$ 3% of BSA Units: Subjects			
Yes	162	514	
No	170	482	

End points

End points reporting groups

Reporting group title	Secukinumab 150 mg Without Load
Reporting group description: Participants were subcutaneously (s.c.) administered with 150 milligrams (mg) of secukinumab as 1 milliliter (mL) Pre-Filled Syringe (PFS) and secukinumab matching placebo (1 mL PFS) at baseline. Participants received secukinumab matching placebo (2*1 mL PFS) at Weeks 1, 2 and 3. From week 4 participants received secukinumab 150 mg (1 mL PFS) and secukinumab matching placebo (1 mL PFS) every four weeks up to 100 weeks.	
Reporting group title	Secukinumab 150 mg With Load
Reporting group description: Participants were s.c. administered with 150 mg of secukinumab as 1 mL PFS and secukinumab matching placebo (1 mL PFS) at baseline, weeks 1, 2 and 3, followed by dosing every four weeks starting at Week 4 up to 100.	
Reporting group title	Secukinumab 300 mg With Load
Reporting group description: Participants were s.c. administered with 300 mg of secukinumab as 2*1 mL PFS (150 mg dose) at baseline, weeks 1, 2 and 3, followed by dosing every four weeks starting at Week 4 up to 100 weeks.	
Reporting group title	Placebo
Reporting group description: Participants were s.c. administered with secukinumab matching placebo (2*1 mL PFS) at baseline, weeks 1, 2 and 3, followed by dosing every four weeks starting at Week 4. Participants were further randomized to two different treatment sequences in 1:1 ratio at baseline as secukinumab matching placebo till Week 16/24 followed by secukinumab 150 mg every 4 weeks starting at Week 16/24 up to 100 weeks and secukinumab matching placebo till Week 16/24 followed by secukinumab 300 mg every 4 weeks starting at Week 16/24 up to 100 weeks.	

Primary: Percentage of Participants With Active Psoriatic Arthritis (PsA) Achieving an American College of Rheumatology Response 20 (ACR20) at Week 16

End point title	Percentage of Participants With Active Psoriatic Arthritis (PsA) Achieving an American College of Rheumatology Response 20 (ACR20) at Week 16
End point description: ACR20 response was defined as having a positive clinical response to treatment (individual improvement) in disease activity if the participant had at least 20% improvement based on tender 78-joint count, swollen 76-joint count and at least 20% improvement in 3 of the following 5 measures: participant's assessment of PsA pain, patient's global assessment of disease activity, physician's global assessment of disease activity, participant's self-assessed disability (Health Assessment Questionnaire Disability Index (HAQ-DI) score), and acute phase reactant evaluated as (high sensitivity c-reactive protein (hsCRP) or erythrocyte sedimentation rate (ESR)).	
End point type	Primary
End point timeframe: Week 16	

End point values	Secukinumab 150 mg Without Load	Secukinumab 150 mg With Load	Secukinumab 300 mg With Load	Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	222	220	222	332
Units: percentage of participants				
number (not applicable)	59.5	55.5	62.6	27.4

Statistical analyses

Statistical analysis title	Secukinumab 150 mg Without Load, Placebo
Statistical analysis description: Statistical values were calculated from a logistic regression model with treatment and randomization stratum (TNF-a status -naive or Incidence Rate) as factors and baseline weight as a covariate.	
Comparison groups	Secukinumab 150 mg Without Load v Placebo
Number of subjects included in analysis	554
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.0001
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	4.02
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.78
upper limit	5.79

Statistical analysis title	Secukinumab 150 mg With Load
Statistical analysis description: Statistical values were calculated from a logistic regression model with treatment and randomization stratum (TNF-a status -naive or Incidence Rate) as factors and baseline weight as a covariate.	
Comparison groups	Secukinumab 150 mg With Load v Placebo
Number of subjects included in analysis	552
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.0001
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	3.38
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.35
upper limit	4.87

Statistical analysis title	Secukinumab 300 mg With Load
-----------------------------------	------------------------------

Statistical analysis description:

Statistical values were calculated from a logistic regression model with treatment and randomization

stratum (TNF- α status -naive or Incidence Rate) as factors and baseline weight as a covariate.

Comparison groups	Secukinumab 300 mg With Load v Placebo
Number of subjects included in analysis	554
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.0001
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	4.58
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.16
upper limit	6.63

Secondary: Change from baseline to Week 24 with secukinumab compared with placebo for joint/bone structural damage (using van der Heijde modified total Sharp score (mTSS))

End point title	Change from baseline to Week 24 with secukinumab compared with placebo for joint/bone structural damage (using van der Heijde modified total Sharp score (mTSS))
-----------------	--

End point description:

PsA modified vdH-mTSS scoring method was used to assess bone erosion & joint space narrowing (JSN) in hands & feet; that included the 2nd through 5th distal interphalangeal (DIP) joints of each hand. Maximum score for erosions was 5 in joints of the hands and 10 in joints of the feet with 0=no erosions, 1=discrete erosion, 2=large erosion not passing the mid-line, and 3=large erosion passing the mid-line. JSN is: 0=normal, 1=asymmetrical or minimal narrowing up to a maximum of 25%, 2 = definite narrowing with loss of up to 50% of the normal space, 3 = definite narrowing with loss of 50–99% of the normal space, and 4 = absence of a joint space. Maximum erosion score is 320 (200 for the hands and 120 for the feet), and the max total JSN score is 208 (160 for the hands and 48 for the feet). Total radiographic score (hands & feet combined) ranges from 0 to 528, where higher scores indicate more articular damage

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 24

End point values	Secukinumab 150 mg Without Load	Secukinumab 150 mg With Load	Secukinumab 300 mg With Load	Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	222	220	222	332 ^[1]
Units: Sharp score				
arithmetic mean (standard error)	-0.10 ($\pm$ 0.22)	0.13 ($\pm$ 0.13)	0.02 ($\pm$ 0.13)	0.50 ($\pm$ 0)

Notes:

[1] - Placebo cannot be compared to itself

Statistical analyses

No statistical analyses for this end point

Secondary: Count and Percentage of patients achieving Psoriatic Area and Severity Index 75 (PASI75) response

End point title	Count and Percentage of patients achieving Psoriatic Area and Severity Index 75 (PASI75) response
-----------------	---

End point description:

The efficacy of secukinumab 150 mg (with or without loading regimen), or 300 mg (with loading regimen) at Week 16 compared with placebo based on the proportion of patients achieving Psoriatic Area and Severity Index 75 (PASI75) response.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 16

End point values	Secukinumab 150 mg Without Load	Secukinumab 150 mg With Load	Secukinumab 300 mg With Load	Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	117	125	110	162
Units: participants	68	75	77	20

Statistical analyses

Statistical analysis title	Secukinumab 150 mg Without Load
-----------------------------------	---------------------------------

Statistical analysis description:

Odds ratio, 95% confidence interval, and p-value are from a logistic regression model with treatment and randomization stratum (TNF-alpha status -naïve or IR) as factors and baseline weight as a covariate.

Comparison groups	Secukinumab 150 mg Without Load v Placebo
Number of subjects included in analysis	279
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.0001
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	10.15
Confidence interval	
level	95 %
sides	2-sided
lower limit	5.52
upper limit	18.63

Statistical analysis title	Secukinumab 150 mg With Load
-----------------------------------	------------------------------

Statistical analysis description:

Odds ratio, 95% confidence interval, and p-value are from a logistic regression model with treatment and randomization stratum (TNF-alpha status -naïve or IR) as factors and baseline weight as a covariate.

Comparison groups	Secukinumab 150 mg With Load v Placebo
-------------------	--

Number of subjects included in analysis	287
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.0001
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	11.66
Confidence interval	
level	95 %
sides	2-sided
lower limit	6.37
upper limit	21.37

Statistical analysis title	Secukinumab 300 mg With Load
-----------------------------------	------------------------------

Statistical analysis description:

Odds ratio, 95% confidence interval, and p-value are from a logistic regression model with treatment and randomization stratum (TNF-alpha status -naïve or IR) as factors and baseline weight as a covariate.

Comparison groups	Secukinumab 300 mg With Load v Placebo
Number of subjects included in analysis	272
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.0001
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	18.06
Confidence interval	
level	95 %
sides	2-sided
lower limit	9.56
upper limit	34.12

Secondary: Count and Percentage of patients achieving Psoriatic Area and Severity Index 90 (PASI90) response

End point title	Count and Percentage of patients achieving Psoriatic Area and Severity Index 90 (PASI90) response
-----------------	---

End point description:

The efficacy of secukinumab 150 mg (with or without loading regimen), or 300 mg (with loading regimen) at Week 16 compared with placebo based on the proportion of patients achieving Psoriatic Area and Severity Index 90 (PASI90) response.

End point type	Secondary
End point timeframe:	
16 weeks	

End point values	Secukinumab 150 mg Without Load	Secukinumab 150 mg With Load	Secukinumab 300 mg With Load	Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	117	125	110	162
Units: participants	37	46	59	15

Statistical analyses

Statistical analysis title	Secukinumab 150 mg Without Load
Statistical analysis description:	
Odds ratio, 95% confidence interval, and p-value are from a logistic regression model with treatment and randomization stratum (TNF-alpha status -naïve or IR) as factors and baseline weight as a covariate. Missing responses are imputed as non-responders.	
Comparison groups	Secukinumab 150 mg Without Load v Placebo
Number of subjects included in analysis	279
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.0001
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	4.51
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.31
upper limit	8.83

Statistical analysis title	Secukinumab 150 mg With Load
Statistical analysis description:	
Odds ratio, 95% confidence interval, and p-value are from a logistic regression model with treatment and randomization stratum (TNF-alpha status -naïve or IR) as factors and baseline weight as a covariate. Missing responses are imputed as non-responders.	
Comparison groups	Secukinumab 150 mg With Load v Placebo
Number of subjects included in analysis	287
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.0001
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	6.14
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.18
upper limit	11.87

Statistical analysis title	Secukinumab 300 mg With Load
Statistical analysis description: Odds ratio, 95% confidence interval, and p-value are from a logistic regression model with treatment and randomization stratum (TNF-alpha status -naïve or IR) as factors and baseline weight as a covariate. Missing responses are imputed as non-responders.	
Comparison groups	Secukinumab 300 mg With Load v Placebo
Number of subjects included in analysis	272
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.0001
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	12.55
Confidence interval	
level	95 %
sides	2-sided
lower limit	6.43
upper limit	24.48

Secondary: Count and Percentage of patients achieving an ACR50 response

End point title	Count and Percentage of patients achieving an ACR50 response
End point description: ACR 50 Response is a measure based on American College of Rheumatology criteria of at least a 50% improvement in the number of tender and swollen joints, and a 50% improvement in at least 3 of the following: the patient's global assessment of disease status; the patient's assessment of pain; the patient's assessment of function measured using the Stanford Health Assessment Questionnaire the physician's global assessment of disease status; serum C-reactive protein levels.	
End point type	Secondary
End point timeframe: 16 weeks	

End point values	Secukinumab 150 mg Without Load	Secukinumab 150 mg With Load	Secukinumab 300 mg With Load	Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	222	220	222	332
Units: participants	71	79	88	27

Statistical analyses

Statistical analysis title	Secukinumab 150 mg Without Load
-----------------------------------	---------------------------------

Statistical analysis description:

Odds ratio, 95% confidence interval, and p-value are from a logistic regression model with treatment and randomization stratum (TNF-alpha status -naïve or IR) as factors and baseline weight as a covariate.

Comparison groups	Secukinumab 150 mg Without Load v Placebo
Number of subjects included in analysis	554
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.0001
Method	Regression, Logistic
Parameter estimate	Log odds ratio
Point estimate	5.37
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.3
upper limit	8.73

Statistical analysis title

Secukinumab 150 mg With Load

Statistical analysis description:

Odds ratio, 95% confidence interval, and p-value are from a logistic regression model with treatment and randomization stratum (TNF-alpha status -naïve or IR) as factors and baseline weight as a covariate.

Comparison groups	Secukinumab 150 mg With Load v Placebo
Number of subjects included in analysis	552
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.0001
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	6.37
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.93
upper limit	10.32

Statistical analysis title

Secukinumab 300 mg With Load

Statistical analysis description:

Odds ratio, 95% confidence interval, and p-value are from a logistic regression model with treatment and randomization stratum (TNF-alpha status -naïve or IR) as factors and baseline weight as a covariate.

Comparison groups	Secukinumab 300 mg With Load v Placebo
-------------------	--

Number of subjects included in analysis	554
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.0001
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	7.43
Confidence interval	
level	95 %
sides	2-sided
lower limit	4.61
upper limit	12

Secondary: Change from baseline in HAQ-DI© score

End point title	Change from baseline in HAQ-DI© score
End point description:	The change (within treatment) on secukinumab 150 mg (with or without loading regimen), or 300 mg (with loading regimen), at Week 16 compared with placebo for the disease activity assessed by the changes in The Health Assessment Questionnaire disability index (HAQ-DI) relative to baseline.
End point type	Secondary
End point timeframe:	16 weeks

End point values	Secukinumab 150 mg Without Load	Secukinumab 150 mg With Load	Secukinumab 300 mg With Load	Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	211	210	211	300
Units: scores on a scale				
least squares mean (standard error)	-0.45 (± 0.035)	-0.44 (± 0.035)	-0.55 (± 0.035)	-0.21 (± 0.029)

Statistical analyses

Statistical analysis title	Secukinumab 150 mg Without Load
Comparison groups	Secukinumab 150 mg Without Load v Placebo
Number of subjects included in analysis	511
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Treatment contrast in LS mean (Change)
Point estimate	-0.24

Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.32
upper limit	-0.15
Variability estimate	Standard error of the mean
Dispersion value	0.045

Statistical analysis title	Secukinumab 150 mg With Load
Comparison groups	Secukinumab 150 mg With Load v Placebo
Number of subjects included in analysis	510
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Treatment Contrast in LS mean (Change)
Point estimate	-0.23
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.32
upper limit	-0.14
Variability estimate	Standard error of the mean
Dispersion value	0.045

Statistical analysis title	Secukinumab 300 mg With Load
Comparison groups	Secukinumab 300 mg With Load v Placebo
Number of subjects included in analysis	511
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Treatment Contrast inj LS mean (Change)
Point estimate	-0.33
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.42
upper limit	-0.24
Variability estimate	Standard error of the mean
Dispersion value	0.045

Secondary: Change from baseline in Disease Activity Score for 28 joints (DAS28-CRP) (utilizing High sensitivity C-Reactive Protein (hsCRP))

End point title	Change from baseline in Disease Activity Score for 28 joints (DAS28-CRP) (utilizing High sensitivity C-Reactive Protein (hsCRP))
End point description: The improvement on secukinumab 150 mg (with or without loading regimen), or 300 mg (with loading regimen) at Week 16 compared with placebo for the disease activity assessed by the changes in Disease Activity Score for 28 joints (DAS28-CRP) (utilizing High sensitivity C-Reactive Protein (hsCRP)) relative to baseline.	
Scores range from 0 (no difficulty) to 3 (unable to do)	
End point type	Secondary
End point timeframe: 16 weeks	

End point values	Secukinumab 150 mg Without Load	Secukinumab 150 mg With Load	Secukinumab 300 mg With Load	Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	210	208	209	297
Units: scores on a scale				
least squares mean (standard error)	-1.29 (± 0.074)	-1.29 (± 0.075)	-1.49 (± 0.074)	-0.63 (± 0.062)

Statistical analyses

Statistical analysis title	Secukinumab 150 mg Without Load
Statistical analysis description: Mixed model with treatment regimen, analysis visit and randomization stratum (TNF-alpha status -naïve or IR) as factors, weight and baseline score as continuous covariates, and treatment by analysis visit and baseline score by analysis visit as interaction terms, using an unstructured covariance structure	
Comparison groups	Secukinumab 150 mg Without Load v Placebo
Number of subjects included in analysis	507
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Treatment contrast in LS mean (Change)
Point estimate	-0.66
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.85
upper limit	-0.47
Variability estimate	Standard error of the mean
Dispersion value	0.096

Statistical analysis title	Secukinumab 150 mg With Load
----------------------------	------------------------------

Statistical analysis description:

Mixed model with treatment regimen, analysis visit and randomization stratum (TNF-alpha status -naïve or IR) as factors, weight and baseline score as continuous covariates, and treatment by analysis visit and baseline score by analysis visit as interaction terms, using an unstructured covariance structure

Comparison groups	Secukinumab 150 mg With Load v Placebo
Number of subjects included in analysis	505
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Treatment Contrast in LS Mean (Change)
Point estimate	-0.66
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.85
upper limit	-0.47
Variability estimate	Standard error of the mean
Dispersion value	0.096

Statistical analysis title

Secukinumab 300 mg With Load

Statistical analysis description:

Mixed model with treatment regimen, analysis visit and randomization stratum (TNF-alpha status -naïve or IR) as factors, weight and baseline score as continuous covariates, and treatment by analysis visit and baseline score by analysis visit as interaction terms, using an unstructured covariance structure

Comparison groups	Secukinumab 300 mg With Load v Placebo
Number of subjects included in analysis	506
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis
Parameter estimate	Treatment contrast in LS mean (Change)
Point estimate	-0.86
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.05
upper limit	-0.67
Variability estimate	Standard error of the mean
Dispersion value	0.096

Secondary: Count and Percentage of patients with enthesitis in the subset of patients who had enthesitis at baseline

End point title	Count and Percentage of patients with enthesitis in the subset of patients who had enthesitis at baseline
-----------------	---

End point description:

The efficacy of secukinumab pooled regimen (150 mg with or without loading regimen, and 300 mg with loading regimen) at Week 16 compared with placebo based on the proportion of patients with enthesitis in the subset of patients who had enthesitis at

baseline

End point type	Secondary
End point timeframe:	
16 weeks	

End point values	Secukinumab 150 mg Without Load	Secukinumab 150 mg With Load	Secukinumab 300 mg With Load	Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	129	141	140	192
Units: participants	75	64	62	124

Statistical analyses

Statistical analysis title	Secukinumab 150 mg Without Load
Comparison groups	Secukinumab 150 mg Without Load v Placebo
Number of subjects included in analysis	321
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.225
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	0.75
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.47
upper limit	1.19

Statistical analysis title	Secukinumab 150 mg With Load
Comparison groups	Secukinumab 150 mg With Load v Placebo
Number of subjects included in analysis	333
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0004
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	0.45
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.29
upper limit	0.7

Statistical analysis title	Secukinumab 300 mg With Load
Comparison groups	Secukinumab 300 mg With Load v Placebo
Number of subjects included in analysis	332
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0004
Method	Regression, Logistic
Parameter estimate	Log odds ratio
Point estimate	0.44
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.28
upper limit	0.69

Secondary: Count and Percentage of Participants with dactylitis in the subset of patients who have dactylitis at baseline

End point title	Count and Percentage of Participants with dactylitis in the subset of patients who have dactylitis at baseline
End point description:	
The efficacy of secukinumab pooled regimen (150 mg with or without loading regimen, and 300 mg with loading regimen) at Week 16 compared with placebo based on the proportion of patients with dactylitis in the subset of patients who have dactylitis at baseline	
End point type	Secondary
End point timeframe:	
16 weeks	

End point values	Secukinumab 150 mg Without Load	Secukinumab 150 mg With Load	Secukinumab 300 mg With Load	Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	103	80	82	124
Units: Participants	45	34	28	84

Statistical analyses

Statistical analysis title	Secukinumab 150 mg Without Load
Comparison groups	Secukinumab 150 mg Without Load v Placebo

Number of subjects included in analysis	227
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0004
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	0.37
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.22
upper limit	0.65

Statistical analysis title	Secukinumab 150 mg With Load
Comparison groups	Secukinumab 150 mg With Load v Placebo
Number of subjects included in analysis	204
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0003
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	0.34
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.19
upper limit	0.6

Statistical analysis title	Secukinumab 300 mg With Load
Comparison groups	Secukinumab 300 mg With Load v Placebo
Number of subjects included in analysis	206
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	0.24
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.13
upper limit	0.44

Adverse events

Adverse events information

Timeframe for reporting adverse events:

AEs & SAEs were collected for maximum duration of treatment & follow up for a participant per protocol for approximately 24 weeks. All cause mortality was collected for as long as participants could be contacted from FPFV until LPLV up to a max of 24 wks

Adverse event reporting additional description:

An Adverse Event (AE) is any sign or symptom that occurs during the study treatment plus 28 days post treatment

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	20.0
--------------------	------

Reporting groups

Reporting group title	Secukinumab 150 mg Without Load
-----------------------	---------------------------------

Reporting group description:

Participants were s.c. administered with 150 milligrams (mg) of secukinumab as 1 mL PFS and secukinumab matching placebo (1.0 mL PFS) at baseline. Participants received secukinumab matching placebo (2*1 mL PFS) at Weeks 1, 2 and 3. From week 4 participants received secukinumab 150 mg (1 mL PFS) and secukinumab matching placebo (1 mL PFS) every four weeks up to 100 weeks.

Reporting group title	Secukinumab 150 mg With Load
-----------------------	------------------------------

Reporting group description:

Participants were s.c. administered with 150 mg of secukinumab as 1 mL PFS and secukinumab matching placebo (1.0 mL PFS) at baseline, weeks 1, 2 and 3, followed by dosing every four weeks starting at Week 4 up to 100.

Reporting group title	Secukinumab 300 mg With Load
-----------------------	------------------------------

Reporting group description:

Participants were s.c. administered with 300 mg of secukinumab as 2*1 mL PFS (150 mg dose) at baseline, weeks 1, 2 and 3, followed by dosing every four weeks starting at Week 4 up to 100 weeks.

Reporting group title	Secukinumab Total
-----------------------	-------------------

Reporting group description:

Participants were s.c. administered with secukinumab and secukinumab matching placebo at baseline, weeks 1, 2 and 3, followed by dosing every four weeks starting at Week 4 up to 100.

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Participants were s.c. administered with secukinumab matching placebo (2*1 mL PFS) at baseline, weeks 1, 2 and 3, followed by dosing every four weeks starting at Week 4. Participants were further randomized to two different treatment sequences in 1:1 ratio at baseline as secukinumab matching placebo till Week 16/24 followed by secukinumab 150 mg every 4 weeks starting at Week 16/24 up to 100 weeks and secukinumab matching placebo till Week 16/24 followed by secukinumab 300 mg every 4 weeks starting at Week 16/24 up to 100 weeks.

Serious adverse events	Secukinumab 150 mg Without Load	Secukinumab 150 mg With Load	Secukinumab 300 mg With Load
Total subjects affected by serious adverse events			
subjects affected / exposed	6 / 222 (2.70%)	9 / 220 (4.09%)	7 / 222 (3.15%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			

Basal cell carcinoma			
subjects affected / exposed	1 / 222 (0.45%)	0 / 220 (0.00%)	0 / 222 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant melanoma			
subjects affected / exposed	1 / 222 (0.45%)	0 / 220 (0.00%)	0 / 222 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Circulatory collapse			
subjects affected / exposed	1 / 222 (0.45%)	0 / 220 (0.00%)	0 / 222 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Deep vein thrombosis			
subjects affected / exposed	0 / 222 (0.00%)	0 / 220 (0.00%)	0 / 222 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pregnancy, puerperium and perinatal conditions			
Abortion spontaneous			
subjects affected / exposed	0 / 222 (0.00%)	1 / 220 (0.45%)	0 / 222 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ectopic pregnancy			
subjects affected / exposed	0 / 222 (0.00%)	1 / 220 (0.45%)	0 / 222 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Non-cardiac chest pain			
subjects affected / exposed	0 / 222 (0.00%)	0 / 220 (0.00%)	1 / 222 (0.45%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Anaphylactic reaction			

subjects affected / exposed	0 / 222 (0.00%)	0 / 220 (0.00%)	1 / 222 (0.45%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	1 / 222 (0.45%)	0 / 220 (0.00%)	0 / 222 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 222 (0.00%)	0 / 220 (0.00%)	0 / 222 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Suicidal ideation			
subjects affected / exposed	0 / 222 (0.00%)	1 / 220 (0.45%)	0 / 222 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Computerised tomogram thorax abnormal			
subjects affected / exposed	0 / 222 (0.00%)	1 / 220 (0.45%)	0 / 222 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Ankle fracture			
subjects affected / exposed	0 / 222 (0.00%)	0 / 220 (0.00%)	1 / 222 (0.45%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Concussion			
subjects affected / exposed	0 / 222 (0.00%)	0 / 220 (0.00%)	1 / 222 (0.45%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foreign body			

subjects affected / exposed	0 / 222 (0.00%)	1 / 220 (0.45%)	0 / 222 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hip fracture			
subjects affected / exposed	0 / 222 (0.00%)	1 / 220 (0.45%)	0 / 222 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Humerus fracture			
subjects affected / exposed	0 / 222 (0.00%)	1 / 220 (0.45%)	0 / 222 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Road traffic accident			
subjects affected / exposed	0 / 222 (0.00%)	0 / 220 (0.00%)	0 / 222 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tibia fracture			
subjects affected / exposed	0 / 222 (0.00%)	0 / 220 (0.00%)	1 / 222 (0.45%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ulna fracture			
subjects affected / exposed	1 / 222 (0.45%)	0 / 220 (0.00%)	0 / 222 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Coronary artery disease			
subjects affected / exposed	0 / 222 (0.00%)	1 / 220 (0.45%)	0 / 222 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			
subjects affected / exposed	0 / 222 (0.00%)	1 / 220 (0.45%)	0 / 222 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			

Carotid artery stenosis			
subjects affected / exposed	0 / 222 (0.00%)	0 / 220 (0.00%)	0 / 222 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Polyneuropathy			
subjects affected / exposed	0 / 222 (0.00%)	0 / 220 (0.00%)	0 / 222 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sciatica			
subjects affected / exposed	0 / 222 (0.00%)	1 / 220 (0.45%)	0 / 222 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transient ischaemic attack			
subjects affected / exposed	0 / 222 (0.00%)	0 / 220 (0.00%)	1 / 222 (0.45%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Thrombocytopenia			
subjects affected / exposed	0 / 222 (0.00%)	0 / 220 (0.00%)	0 / 222 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Colitis ulcerative			
subjects affected / exposed	0 / 222 (0.00%)	1 / 220 (0.45%)	0 / 222 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Crohn's disease			
subjects affected / exposed	1 / 222 (0.45%)	0 / 220 (0.00%)	0 / 222 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulum			
subjects affected / exposed	0 / 222 (0.00%)	0 / 220 (0.00%)	0 / 222 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Rectal haemorrhage			
subjects affected / exposed	0 / 222 (0.00%)	0 / 220 (0.00%)	0 / 222 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Psoriasis			
subjects affected / exposed	0 / 222 (0.00%)	0 / 220 (0.00%)	0 / 222 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Renal colic			
subjects affected / exposed	0 / 222 (0.00%)	0 / 220 (0.00%)	0 / 222 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthritis			
subjects affected / exposed	0 / 222 (0.00%)	0 / 220 (0.00%)	0 / 222 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chondropathy			
subjects affected / exposed	0 / 222 (0.00%)	0 / 220 (0.00%)	0 / 222 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 222 (0.00%)	0 / 220 (0.00%)	1 / 222 (0.45%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rotator cuff syndrome			
subjects affected / exposed	0 / 222 (0.00%)	0 / 220 (0.00%)	0 / 222 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Synovitis			

subjects affected / exposed	0 / 222 (0.00%)	0 / 220 (0.00%)	0 / 222 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Cellulitis			
subjects affected / exposed	0 / 222 (0.00%)	0 / 220 (0.00%)	0 / 222 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Otitis externa			
subjects affected / exposed	0 / 222 (0.00%)	0 / 220 (0.00%)	0 / 222 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tonsillitis			
subjects affected / exposed	1 / 222 (0.45%)	0 / 220 (0.00%)	0 / 222 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Typhoid fever			
subjects affected / exposed	0 / 222 (0.00%)	1 / 220 (0.45%)	0 / 222 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection			
subjects affected / exposed	0 / 222 (0.00%)	0 / 220 (0.00%)	0 / 222 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Secukinumab Total	Placebo	
Total subjects affected by serious adverse events			
subjects affected / exposed	25 / 822 (3.04%)	12 / 332 (3.61%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal cell carcinoma			

subjects affected / exposed	1 / 822 (0.12%)	0 / 332 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant melanoma			
subjects affected / exposed	1 / 822 (0.12%)	0 / 332 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Circulatory collapse			
subjects affected / exposed	1 / 822 (0.12%)	0 / 332 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Deep vein thrombosis			
subjects affected / exposed	0 / 822 (0.00%)	1 / 332 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pregnancy, puerperium and perinatal conditions			
Abortion spontaneous			
subjects affected / exposed	1 / 822 (0.12%)	0 / 332 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ectopic pregnancy			
subjects affected / exposed	1 / 822 (0.12%)	0 / 332 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Non-cardiac chest pain			
subjects affected / exposed	1 / 822 (0.12%)	0 / 332 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
Anaphylactic reaction			

subjects affected / exposed	1 / 822 (0.12%)	0 / 332 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	1 / 822 (0.12%)	0 / 332 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary embolism			
subjects affected / exposed	0 / 822 (0.00%)	1 / 332 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Suicidal ideation			
subjects affected / exposed	1 / 822 (0.12%)	0 / 332 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Computerised tomogram thorax abnormal			
subjects affected / exposed	1 / 822 (0.12%)	0 / 332 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Ankle fracture			
subjects affected / exposed	1 / 822 (0.12%)	0 / 332 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Concussion			
subjects affected / exposed	1 / 822 (0.12%)	0 / 332 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foreign body			

subjects affected / exposed	1 / 822 (0.12%)	0 / 332 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hip fracture			
subjects affected / exposed	1 / 822 (0.12%)	0 / 332 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Humerus fracture			
subjects affected / exposed	1 / 822 (0.12%)	0 / 332 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Road traffic accident			
subjects affected / exposed	0 / 822 (0.00%)	1 / 332 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tibia fracture			
subjects affected / exposed	1 / 822 (0.12%)	0 / 332 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ulna fracture			
subjects affected / exposed	1 / 822 (0.12%)	0 / 332 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Coronary artery disease			
subjects affected / exposed	1 / 822 (0.12%)	0 / 332 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocardial infarction			
subjects affected / exposed	1 / 822 (0.12%)	0 / 332 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			

Carotid artery stenosis			
subjects affected / exposed	0 / 822 (0.00%)	1 / 332 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Polyneuropathy			
subjects affected / exposed	0 / 822 (0.00%)	1 / 332 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sciatica			
subjects affected / exposed	1 / 822 (0.12%)	0 / 332 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transient ischaemic attack			
subjects affected / exposed	1 / 822 (0.12%)	0 / 332 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Thrombocytopenia			
subjects affected / exposed	1 / 822 (0.12%)	0 / 332 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Colitis ulcerative			
subjects affected / exposed	1 / 822 (0.12%)	0 / 332 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Crohn's disease			
subjects affected / exposed	1 / 822 (0.12%)	0 / 332 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diverticulum			
subjects affected / exposed	0 / 822 (0.00%)	1 / 332 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Rectal haemorrhage			
subjects affected / exposed	0 / 822 (0.00%)	1 / 332 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Psoriasis			
subjects affected / exposed	1 / 822 (0.12%)	0 / 332 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Renal colic			
subjects affected / exposed	0 / 822 (0.00%)	1 / 332 (0.30%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	1 / 1	
Musculoskeletal and connective tissue disorders			
Arthritis			
subjects affected / exposed	0 / 822 (0.00%)	1 / 332 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chondropathy			
subjects affected / exposed	0 / 822 (0.00%)	1 / 332 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal chest pain			
subjects affected / exposed	1 / 822 (0.12%)	0 / 332 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rotator cuff syndrome			
subjects affected / exposed	0 / 822 (0.00%)	1 / 332 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Synovitis			

subjects affected / exposed	0 / 822 (0.00%)	1 / 332 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Cellulitis			
subjects affected / exposed	0 / 822 (0.00%)	2 / 332 (0.60%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Otitis externa			
subjects affected / exposed	0 / 822 (0.00%)	1 / 332 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tonsillitis			
subjects affected / exposed	1 / 822 (0.12%)	0 / 332 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Typhoid fever			
subjects affected / exposed	1 / 822 (0.12%)	0 / 332 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Viral infection			
subjects affected / exposed	0 / 822 (0.00%)	1 / 332 (0.30%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 2 %

Non-serious adverse events	Secukinumab 150 mg Without Load	Secukinumab 150 mg With Load	Secukinumab 300 mg With Load
Total subjects affected by non-serious adverse events			
subjects affected / exposed	95 / 222 (42.79%)	82 / 220 (37.27%)	83 / 222 (37.39%)
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	3 / 222 (1.35%)	5 / 220 (2.27%)	2 / 222 (0.90%)
occurrences (all)	3	5	2

Fall subjects affected / exposed occurrences (all)	5 / 222 (2.25%) 5	1 / 220 (0.45%) 1	0 / 222 (0.00%) 0
Vascular disorders Hypertension subjects affected / exposed occurrences (all)	9 / 222 (4.05%) 9	5 / 220 (2.27%) 5	8 / 222 (3.60%) 8
Nervous system disorders Headache subjects affected / exposed occurrences (all)	8 / 222 (3.60%) 8	9 / 220 (4.09%) 9	5 / 222 (2.25%) 5
Blood and lymphatic system disorders Leukopenia subjects affected / exposed occurrences (all)	1 / 222 (0.45%) 0	1 / 220 (0.45%) 0	6 / 222 (2.70%) 0
General disorders and administration site conditions Fatigue subjects affected / exposed occurrences (all)	4 / 222 (1.80%) 4	4 / 220 (1.82%) 4	4 / 222 (1.80%) 4
Gastrointestinal disorders Diarrhoea subjects affected / exposed occurrences (all) Nausea subjects affected / exposed occurrences (all) Vomiting subjects affected / exposed occurrences (all)	7 / 222 (3.15%) 7 7 / 222 (3.15%) 7 3 / 222 (1.35%) 3	4 / 220 (1.82%) 4 4 / 220 (1.82%) 4 6 / 220 (2.73%) 6	9 / 222 (4.05%) 9 3 / 222 (1.35%) 3 2 / 222 (0.90%) 2
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all) Oropharyngeal pain subjects affected / exposed occurrences (all)	7 / 222 (3.15%) 7 5 / 222 (2.25%) 5	2 / 220 (0.91%) 2 5 / 220 (2.27%) 5	4 / 222 (1.80%) 4 5 / 222 (2.25%) 5
Skin and subcutaneous tissue disorders			

Pruritus subjects affected / exposed occurrences (all)	2 / 222 (0.90%) 2	11 / 220 (5.00%) 11	3 / 222 (1.35%) 3
Psoriasis subjects affected / exposed occurrences (all)	3 / 222 (1.35%) 3	3 / 220 (1.36%) 3	3 / 222 (1.35%) 3
Psychiatric disorders Anxiety subjects affected / exposed occurrences (all)	1 / 222 (0.45%) 1	5 / 220 (2.27%) 5	0 / 222 (0.00%) 0
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	3 / 222 (1.35%) 3	4 / 220 (1.82%) 4	4 / 222 (1.80%) 4
Back pain subjects affected / exposed occurrences (all)	8 / 222 (3.60%) 8	4 / 220 (1.82%) 4	4 / 222 (1.80%) 4
Psoriatic arthropathy subjects affected / exposed occurrences (all)	3 / 222 (1.35%) 3	3 / 220 (1.36%) 3	0 / 222 (0.00%) 0
Infections and infestations Bronchitis subjects affected / exposed occurrences (all)	3 / 222 (1.35%) 3	1 / 220 (0.45%) 1	8 / 222 (3.60%) 8
Influenza subjects affected / exposed occurrences (all)	2 / 222 (0.90%) 2	4 / 220 (1.82%) 4	5 / 222 (2.25%) 5
Oral herpes subjects affected / exposed occurrences (all)	3 / 222 (1.35%) 3	0 / 220 (0.00%) 0	5 / 222 (2.25%) 5
Rhinitis subjects affected / exposed occurrences (all)	2 / 222 (0.90%) 2	2 / 220 (0.91%) 2	7 / 222 (3.15%) 7
Upper respiratory tract infection subjects affected / exposed occurrences (all)	14 / 222 (6.31%) 14	17 / 220 (7.73%) 17	7 / 222 (3.15%) 7

Urinary tract infection subjects affected / exposed occurrences (all)	6 / 222 (2.70%) 6	8 / 220 (3.64%) 8	6 / 222 (2.70%) 6
Viral upper respiratory tract infection subjects affected / exposed occurrences (all)	13 / 222 (5.86%) 13	15 / 220 (6.82%) 15	14 / 222 (6.31%) 14
Metabolism and nutrition disorders			
Dyslipidaemia subjects affected / exposed occurrences (all)	8 / 222 (3.60%) 8	4 / 220 (1.82%) 4	8 / 222 (3.60%) 8
Hypercholesterolaemia subjects affected / exposed occurrences (all)	8 / 222 (3.60%) 8	9 / 220 (4.09%) 9	3 / 222 (1.35%) 3
Hyperlipidaemia subjects affected / exposed occurrences (all)	1 / 222 (0.45%) 1	5 / 220 (2.27%) 5	3 / 222 (1.35%) 3

Non-serious adverse events	Secukinumab Total	Placebo	
Total subjects affected by non-serious adverse events subjects affected / exposed	275 / 822 (33.45%)	127 / 332 (38.25%)	
Injury, poisoning and procedural complications			
Contusion subjects affected / exposed occurrences (all)	10 / 822 (1.22%) 10	1 / 332 (0.30%) 1	
Fall subjects affected / exposed occurrences (all)	6 / 822 (0.73%) 6	2 / 332 (0.60%) 2	
Vascular disorders			
Hypertension subjects affected / exposed occurrences (all)	22 / 822 (2.68%) 22	10 / 332 (3.01%) 10	
Nervous system disorders			
Headache subjects affected / exposed occurrences (all)	23 / 822 (2.80%) 23	13 / 332 (3.92%) 13	
Blood and lymphatic system disorders			

Leukopenia subjects affected / exposed occurrences (all)	11 / 822 (1.34%) 0	1 / 332 (0.30%) 0	
General disorders and administration site conditions Fatigue subjects affected / exposed occurrences (all)	12 / 822 (1.46%) 12	8 / 332 (2.41%) 8	
Gastrointestinal disorders Diarrhoea subjects affected / exposed occurrences (all) Nausea subjects affected / exposed occurrences (all) Vomiting subjects affected / exposed occurrences (all)	21 / 822 (2.55%) 21 14 / 822 (1.70%) 14 12 / 822 (1.46%) 12	22 / 332 (6.63%) 22 12 / 332 (3.61%) 12 2 / 332 (0.60%) 2	
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all) Oropharyngeal pain subjects affected / exposed occurrences (all)	14 / 822 (1.70%) 14 16 / 822 (1.95%) 16	6 / 332 (1.81%) 6 6 / 332 (1.81%) 6	
Skin and subcutaneous tissue disorders Pruritus subjects affected / exposed occurrences (all) Psoriasis subjects affected / exposed occurrences (all)	16 / 822 (1.95%) 16 11 / 822 (1.34%) 11	4 / 332 (1.20%) 4 12 / 332 (3.61%) 12	
Psychiatric disorders Anxiety subjects affected / exposed occurrences (all)	6 / 822 (0.73%) 6	1 / 332 (0.30%) 1	
Musculoskeletal and connective tissue disorders			

Arthralgia			
subjects affected / exposed	12 / 822 (1.46%)	10 / 332 (3.01%)	
occurrences (all)	12	10	
Back pain			
subjects affected / exposed	16 / 822 (1.95%)	12 / 332 (3.61%)	
occurrences (all)	16	12	
Psoriatic arthropathy			
subjects affected / exposed	7 / 822 (0.85%)	7 / 332 (2.11%)	
occurrences (all)	7	7	
Infections and infestations			
Bronchitis			
subjects affected / exposed	12 / 822 (1.46%)	2 / 332 (0.60%)	
occurrences (all)	12	2	
Influenza			
subjects affected / exposed	12 / 822 (1.46%)	3 / 332 (0.90%)	
occurrences (all)	12	3	
Oral herpes			
subjects affected / exposed	8 / 822 (0.97%)	4 / 332 (1.20%)	
occurrences (all)	8	4	
Rhinitis			
subjects affected / exposed	11 / 822 (1.34%)	3 / 332 (0.90%)	
occurrences (all)	11	3	
Upper respiratory tract infection			
subjects affected / exposed	38 / 822 (4.62%)	11 / 332 (3.31%)	
occurrences (all)	38	11	
Urinary tract infection			
subjects affected / exposed	20 / 822 (2.43%)	8 / 332 (2.41%)	
occurrences (all)	20	8	
Viral upper respiratory tract infection			
subjects affected / exposed	44 / 822 (5.35%)	29 / 332 (8.73%)	
occurrences (all)	44	29	
Metabolism and nutrition disorders			
Dyslipidaemia			
subjects affected / exposed	23 / 822 (2.80%)	11 / 332 (3.31%)	
occurrences (all)	23	11	
Hypercholesterolaemia			

subjects affected / exposed	20 / 822 (2.43%)	2 / 332 (0.60%)	
occurrences (all)	20	2	
Hyperlipidaemia			
subjects affected / exposed	9 / 822 (1.09%)	2 / 332 (0.60%)	
occurrences (all)	9	2	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
14 February 2018	After a full review of the data, it was confirmed that nineteen patients were impacted by the mapping error, of which, only 10 (1.1%) of the evaluable 936 patients met the criteria of inclusion in the analysis by having both a baseline and post-baseline X-ray. The remaining 9 patients had only baseline X-rays and thus were not included in the radiographic treatment comparison analyses. All possible preventive actions to ensure that this situation will not occur in the future have been taken up with the external radiographic vendor. The purpose of this addendum is to evaluate the effect of using radiographic data from reread X-ray assessments compared to the data from the first read X-rays in patients with inter-reader difference of vdH-mTSS > 8 points between the 2 blinded independent readers. This new analysis was performed after an export mapping error of the 2 sets of X-ray assessments by the external radiographic vendor was identified after Week 24 interim analysis.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported